by BMC
The anti-tumor effects of CD19-targeted chimeric antigen receptor (CAR) T cells may potentially weaken following infusion due to immunogenicity of their antigen-recognition domains, but research...
by Science Immunology
With evidence showing that the scavenger receptor CD5 inhibits chimeric antigen receptor (CAR) T-cell activation, investigators believe that CD5 knockout is the key to improving the clinical...
by AACR
Changes in the oral microbiome may be implicated in the development of oral chronic graft-versus-host disease (cGVHD) in allogenic hematopoietic cell transplantation recipients, based on findings...
by Blood Advances
A retrospective study concluded that idecabtagene vicleucel (ide-cel) works as safely and effectively in older patients with multiple myeloma (MM) as in younger adults, despite a greater presence...
by ASTCT Talks
In a special co-branded episode between Oncology On the Go and the American Society for Transplantation and Cellular Therapy (ASTCT)’s program ASTCT Talks, Rahul Banerjee, MD,...
by Blood Advances
CD70 may be a promising target for preventing acute graft-versus-host disease (aGVHD) after allogeneic hematopoietic stem cell transplantation (allo-HCT) or treating it once it has developed,...